Objective: To compare the short-term effects of rosuvastatin and simvastatin on insulin-resistance and endothelial dysfunction in middle-aged patients with type 2 diabetes and mild untreated dyslipidemia. Methods and design: 29 subjects randomly assigned to rosuvastatin 20 mg/daily or simvastatin 20 mg/daily for 4 weeks. Following data collected both pre- and post- treatment: fasting glucose, lipids, hs CRP, TNF-alpha, insulin sensitivity measured with euglycemic-hyperinsulinemic clamp and flowmediated dilation with brachial artery reactivity technique. Results: Both treatments markedly reduced LDL cholesterol (p<0.001 for both). Insulin sensitivity did not change from relative baseline values in both groups, as well as fasting glucose and adiponectin. Simvastatin significantly improved flow-mediated dilation (p<0.01), to a greater extent than in patients taking rosuvastatin (p=0.09). We found no association between flow-mediated dilation improvement, LDL reduction and changes in hs CRP levels. Conclusion: In type 2 diabetic individuals rosuvastatin was less effective than simvastatin at improving endothelium-dependent vasodilation within one month, without affecting insulin-resistance, adiponectin levels and inflammation.

Bellia, A., Rizza, S., Galli, A., Fabiano, R., Donadel, G., Lombardo, M.f., et al. (2010). Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. ATHEROSCLEROSIS, 210(1), 199-201 [10.1016/j.atherosclerosis.2009.11.021].

Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes

BELLIA, ALFONSO;RIZZA, STEFANO;GALLI, ANGELICA;DONADEL, GIULIA;LOMBARDO, MARCO FELICE;SBRACCIA, PAOLO;TESAURO, MANFREDI;LAURO, DAVIDE
2010-01-01

Abstract

Objective: To compare the short-term effects of rosuvastatin and simvastatin on insulin-resistance and endothelial dysfunction in middle-aged patients with type 2 diabetes and mild untreated dyslipidemia. Methods and design: 29 subjects randomly assigned to rosuvastatin 20 mg/daily or simvastatin 20 mg/daily for 4 weeks. Following data collected both pre- and post- treatment: fasting glucose, lipids, hs CRP, TNF-alpha, insulin sensitivity measured with euglycemic-hyperinsulinemic clamp and flowmediated dilation with brachial artery reactivity technique. Results: Both treatments markedly reduced LDL cholesterol (p<0.001 for both). Insulin sensitivity did not change from relative baseline values in both groups, as well as fasting glucose and adiponectin. Simvastatin significantly improved flow-mediated dilation (p<0.01), to a greater extent than in patients taking rosuvastatin (p=0.09). We found no association between flow-mediated dilation improvement, LDL reduction and changes in hs CRP levels. Conclusion: In type 2 diabetic individuals rosuvastatin was less effective than simvastatin at improving endothelium-dependent vasodilation within one month, without affecting insulin-resistance, adiponectin levels and inflammation.
2010
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/04 - PATOLOGIA GENERALE
Settore MED/09 - MEDICINA INTERNA
Settore MED/13 - ENDOCRINOLOGIA
English
Con Impact Factor ISI
Tumor Necrosis Factor-alpha; Simvastatin; Humans; Lipids; Fluorobenzenes; Cholesterol, LDL; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Endothelium, Vascular; Blood Glucose; C-Reactive Protein; Pyrimidines; Vasodilation; Adult; Diabetes Mellitus, Type 2; Middle Aged; Adiponectin; Insulin Resistance; Sulfonamides; Male; Female
Bellia, A., Rizza, S., Galli, A., Fabiano, R., Donadel, G., Lombardo, M.f., et al. (2010). Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. ATHEROSCLEROSIS, 210(1), 199-201 [10.1016/j.atherosclerosis.2009.11.021].
Bellia, A; Rizza, S; Galli, A; Fabiano, R; Donadel, G; Lombardo, Mf; Cardillo, C; Sbraccia, P; Tesauro, M; Lauro, D
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
EARLY.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 118.89 kB
Formato Adobe PDF
118.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/41969
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 35
social impact